Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio is positioned for success with a variety of upcoming catalysts, including clinical data updates for their CD20-targeted allogeneic gamma delta CAR-T cell therapy in 1H26 and a potential registrational study in 2H26. With a reverse stock split to maintain listing requirements on the NASDAQ and a strong pipeline featuring ADI-001 and ADI-212, the current share price presents an attractive entry point for investors. However, there are risks to consider, such as potential failures to meet efficacy standards and longer enrollment and data presentation timelines.

Bears say

Adicet Bio is a clinical-stage biotechnology company that is currently facing several challenges. These include a relatively new approach to cell therapy, a potential decrease in probability of success for their main product candidate in autoimmune diseases, and risks associated with the regulatory approval process for novel treatments. Additionally, the company has faced financial concerns, with a recent reverse stock split and a decrease in price target due to a dilution of shares and a more conservative NPV valuation. These factors, along with potential manufacturing and currency risks, contribute to the analyst's negative outlook on the stock.

ACET has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 4 analysts, ACET has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.